#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


1-1	0-3	The	_
1-2	4-13	metabolic	_
1-3	14-19	basis	_
1-4	20-22	of	_
1-5	23-32	cognitive	_
1-6	33-40	insight	_
1-7	41-43	in	_
1-8	44-53	psychosis	_
1-9	54-55	:	_
1-10	56-57	A	_
1-11	58-66	positron	_
1-12	67-75	emission	_
1-13	76-86	tomography	_
1-14	87-92	study	_
1-15	93-96	The	_
1-16	97-104	purpose	_
1-17	105-107	of	_
1-18	108-112	this	_
1-19	113-118	study	_
1-20	119-122	was	_
1-21	123-125	to	_
1-22	126-137	investigate	_
1-23	138-141	the	_
1-24	142-154	relationship	_
1-25	155-162	between	_
1-26	163-172	cognitive	_
1-27	173-180	insight	_
1-28	181-184	and	_
1-29	185-193	cerebral	_
1-30	194-204	metabolism	_
1-31	205-207	in	_
1-32	208-216	patients	_
1-33	217-226	suffering	_
1-34	227-231	from	_
1-35	232-241	psychosis	_
1-36	242-243	.	_

2-1	244-247	The	_
2-2	248-252	Beck	http://maven.renci.org/NeuroBridge/neurobridge#CognitiveDisorder
2-3	253-262	Cognitive	http://maven.renci.org/NeuroBridge/neurobridge#CognitiveDisorder
2-4	263-270	Insight	http://maven.renci.org/NeuroBridge/neurobridge#CognitiveDisorder
2-5	271-276	Scale	http://maven.renci.org/NeuroBridge/neurobridge#CognitiveDisorder
2-6	277-278	(	http://maven.renci.org/NeuroBridge/neurobridge#CognitiveDisorder
2-7	279-283	BCIS	http://maven.renci.org/NeuroBridge/neurobridge#CognitiveDisorder
2-8	284-285	)	http://maven.renci.org/NeuroBridge/neurobridge#CognitiveDisorder
2-9	286-289	was	_
2-10	290-302	administered	_
2-11	303-305	to	_
2-12	306-308	63	_
2-13	309-317	patients	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis
2-14	318-322	with	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis
2-15	323-332	psychosis	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis
2-16	333-343	undergoing	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis
2-17	344-352	Positron	http://maven.renci.org/NeuroBridge/neurobridge#PositronEmissionTomography
2-18	353-361	Emission	http://maven.renci.org/NeuroBridge/neurobridge#PositronEmissionTomography
2-19	362-372	Tomography	http://maven.renci.org/NeuroBridge/neurobridge#PositronEmissionTomography
2-20	373-386	investigation	http://maven.renci.org/NeuroBridge/neurobridge#PositronEmissionTomography
2-21	387-388	.	_

3-1	389-392	The	_
3-2	393-399	sample	_
3-3	400-403	was	_
3-4	404-411	divided	_
3-5	412-416	into	_
3-6	417-420	two	_
3-7	421-427	groups	_
3-8	428-439	considering	_
3-9	440-443	the	_
3-10	444-448	BCIS	_
3-11	449-454	score	_
3-12	455-456	.	_

4-1	457-461	Data	_
4-2	462-466	were	_
4-3	467-475	analyzed	_
4-4	476-481	using	_
4-5	482-493	Statistical	_
4-6	494-504	Parametric	_
4-7	505-512	Mapping	_
4-8	513-514	.	_

5-1	515-522	Results	_
5-2	523-524	:	_
5-3	525-533	patients	_
5-4	534-538	with	_
5-5	539-542	low	_
5-6	543-550	insight	_
5-7	551-552	,	_
5-8	553-561	compared	_
5-9	562-564	to	_
5-10	565-570	those	_
5-11	571-575	with	_
5-12	576-580	high	_
5-13	581-588	insight	_
5-14	589-590	,	_
5-15	591-597	showed	_
5-16	598-607	decreased	_
5-17	608-618	metabolism	_
5-18	619-621	in	_
5-19	622-625	the	_
5-20	626-631	right	_
5-21	632-640	fusiform	_
5-22	641-646	gyrus	_
5-23	647-648	,	_
5-24	649-653	left	_
5-25	654-663	precuneus	_
5-26	664-665	,	_
5-27	666-674	superior	_
5-28	675-683	temporal	_
5-29	684-689	gyrus	_
5-30	690-693	and	_
5-31	694-700	insula	_
5-32	701-712	bilaterally	_
5-33	713-714	,	_
5-34	715-717	as	_
5-35	718-722	well	_
5-36	723-725	as	_
5-37	726-735	increased	_
5-38	736-746	metabolism	_
5-39	747-749	in	_
5-40	750-753	the	_
5-41	754-758	left	_
5-42	759-773	orbito-frontal	_
5-43	774-779	gyrus	_
5-44	780-781	(	_
5-45	782-785	all	_
5-46	786-787	p	_
5-47	788-789	<	_
5-48	790-795	0.005	_
5-49	796-797	)	_
5-50	798-799	.	_

6-1	800-803	Our	_
6-2	804-811	results	_
6-3	812-819	suggest	_
6-4	820-824	that	_
6-5	825-832	reduced	_
6-6	833-842	posterior	_
6-7	843-844	(	_
6-8	845-877	occipito-temporo-insulo-parietal	_
6-9	878-879	)	_
6-10	880-883	and	_
6-11	884-893	increased	_
6-12	894-902	anterior	_
6-13	903-904	(	_
6-14	905-918	orbitofrontal	_
6-15	919-920	)	_
6-16	921-929	cerebral	_
6-17	930-940	metabolism	_
6-18	941-944	may	_
6-19	945-952	sustain	_
6-20	953-956	low	_
6-21	957-966	cognitive	_
6-22	967-974	insight	_
6-23	975-977	in	_
6-24	978-987	psychosis	_
6-25	988-989	.	_

7-1	990-991	2	_
7-2	992-993	.	_

8-1	994-1001	Methods	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
8-2	1002-1005	and	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
8-3	1006-1015	materials	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
8-4	1016-1019	2.1	_
8-5	1020-1032	Participants	_
8-6	1033-1044	Sixty-three	_
8-7	1045-1055	inpatients	_
8-8	1056-1057	(	_
8-9	1058-1060	17	_
8-10	1061-1066	women	_
8-11	1067-1070	and	_
8-12	1071-1073	46	_
8-13	1074-1077	men	_
8-14	1078-1079	)	_
8-15	1080-1081	,	_
8-16	1082-1086	aged	_
8-17	1087-1094	between	_
8-18	1095-1097	18	_
8-19	1098-1101	and	_
8-20	1102-1104	65	_
8-21	1105-1110	years	_
8-22	1111-1112	,	_
8-23	1113-1117	with	_
8-24	1118-1123	acute	_
8-25	1124-1133	psychosis	_
8-26	1134-1143	according	_
8-27	1144-1146	to	_
8-28	1147-1150	the	_
8-29	1151-1160	DSM-IV-TR	_
8-30	1161-1162	(	_
8-31	1163-1166	APA	_
8-32	1167-1168	,	_
8-33	1169-1173	2000	_
8-34	1174-1175	)	_
8-35	1176-1184	criteria	_
8-36	1185-1189	were	_
8-37	1190-1198	enrolled	_
8-38	1199-1201	in	_
8-39	1202-1205	the	_
8-40	1206-1213	current	_
8-41	1214-1219	study	_
8-42	1220-1221	.	_

9-1	1222-1232	Thirty-six	_
9-2	1233-1237	were	_
9-3	1238-1247	diagnosed	_
9-4	1248-1252	with	_
9-5	1253-1262	affective	http://maven.renci.org/NeuroBridge/neurobridge#PsychoticDisorder
9-6	1263-1272	psychosis	http://maven.renci.org/NeuroBridge/neurobridge#PsychoticDisorder
9-7	1273-1274	(	_
9-8	1275-1278	all	_
9-9	1279-1283	with	_
9-10	1284-1291	bipolar	_
9-11	1292-1300	disorder	_
9-12	1301-1305	type	_
9-13	1306-1307	I	_
9-14	1308-1309	)	_
9-15	1310-1313	and	_
9-16	1314-1326	twenty-seven	_
9-17	1327-1331	with	_
9-18	1332-1345	non-affective	_
9-19	1346-1355	psychosis	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis
9-20	1356-1357	(	_
9-21	1358-1360	10	_
9-22	1361-1365	with	_
9-23	1366-1379	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
9-24	1380-1381	,	_
9-25	1382-1384	17	_
9-26	1385-1389	with	_
9-27	1390-1399	psychosis	_
9-28	1400-1403	NOS	_
9-29	1404-1405	)	_
9-30	1406-1407	(	_
9-31	1408-1411	for	_
9-32	1412-1419	details	_
9-33	1420-1423	see	_
9-34	1424-1430	Tables	_
9-35	1431-1432	1	_
9-36	1433-1436	and	_
9-37	1437-1438	2	_
9-38	1439-1440	)	_
9-39	1441-1442	.	_

10-1	1443-1452	Exclusion	_
10-2	1453-1461	criteria	_
10-3	1462-1466	were	_
10-4	1467-1476	cognitive	_
10-5	1477-1490	deterioration	_
10-6	1491-1492	(	_
10-7	1493-1498	score	_
10-8	1499-1504	lower	_
10-9	1505-1509	than	_
10-10	1510-1512	24	_
10-11	1513-1514	)	_
10-12	1515-1517	as	_
10-13	1518-1526	assessed	_
10-14	1527-1529	by	_
10-15	1530-1533	the	_
10-16	1534-1545	Mini-Mental	http://maven.renci.org/NeuroBridge/neurobridge#ModifiedMiniMentalState
10-17	1546-1551	State	http://maven.renci.org/NeuroBridge/neurobridge#ModifiedMiniMentalState
10-18	1552-1563	Examination	http://maven.renci.org/NeuroBridge/neurobridge#ModifiedMiniMentalState
10-19	1564-1565	(	http://maven.renci.org/NeuroBridge/neurobridge#ModifiedMiniMentalState
10-20	1566-1570	MMSE	http://maven.renci.org/NeuroBridge/neurobridge#ModifiedMiniMentalState
10-21	1571-1572	)	http://maven.renci.org/NeuroBridge/neurobridge#ModifiedMiniMentalState
10-22	1573-1574	,	_
10-23	1575-1585	consistent	_
10-24	1586-1590	with	_
10-25	1591-1600	normative	_
10-26	1601-1605	data	_
10-27	1606-1608	in	_
10-28	1609-1612	the	_
10-29	1613-1620	Italian	_
10-30	1621-1631	population	_
10-31	1632-1633	,	_
10-32	1634-1636	or	_
10-33	1637-1648	comorbidity	_
10-34	1649-1653	with	_
10-35	1654-1659	other	_
10-36	1660-1672	neurological	_
10-37	1673-1683	conditions	_
10-38	1684-1693	involving	_
10-39	1694-1701	Central	_
10-40	1702-1709	Nervous	_
10-41	1710-1716	System	_
10-42	1717-1718	(	_
10-43	1719-1722	e.g	_
10-44	1723-1724	.	_

11-1	1725-1733	cerebral	_
11-2	1734-1740	tumors	_
11-3	1741-1742	)	_
11-4	1743-1746	and	_
11-5	1747-1756	pregnancy	_
11-6	1757-1759	or	_
11-7	1760-1773	breastfeeding	_
11-8	1774-1775	.	_

12-1	1776-1779	The	_
12-2	1780-1785	study	_
12-3	1786-1789	was	_
12-4	1790-1798	approved	_
12-5	1799-1801	by	_
12-6	1802-1805	the	_
12-7	1806-1811	local	_
12-8	1812-1819	Ethical	_
12-9	1820-1829	Committee	_
12-10	1830-1831	(	_
12-11	1832-1840	Comitato	_
12-12	1841-1846	Etico	_
12-13	1847-1848	,	_
12-14	1849-1859	Fondazione	_
12-15	1860-1861	“	_
12-16	1862-1867	IRCCS	_
12-17	1868-1870	Ca	_
12-18	1871-1872	’	_
12-19	1873-1879	Granda	_
12-20	1880-1881	”	_
12-21	1882-1893	Policlinico	_
12-22	1894-1896	di	_
12-23	1897-1903	Milano	_
12-24	1904-1905	)	_
12-25	1906-1909	and	_
12-26	1910-1918	informed	_
12-27	1919-1926	written	_
12-28	1927-1934	consent	_
12-29	1935-1938	was	_
12-30	1939-1947	obtained	_
12-31	1948-1952	from	_
12-32	1953-1956	all	_
12-33	1957-1965	subjects	_
12-34	1966-1967	.	_

13-1	1968-1976	Capacity	_
13-2	1977-1979	to	_
13-3	1980-1987	consent	_
13-4	1988-1991	was	_
13-5	1992-2002	determined	_
13-6	2003-2010	through	_
13-7	2011-2019	clinical	_
13-8	2020-2029	interview	_
13-9	2030-2033	and	_
13-10	2034-2038	MMSE	_
13-11	2039-2040	,	_
13-12	2041-2043	in	_
13-13	2044-2049	order	_
13-14	2050-2052	to	_
13-15	2053-2059	assess	_
13-16	2060-2063	the	_
13-17	2064-2071	absence	_
13-18	2072-2074	of	_
13-19	2075-2084	cognitive	_
13-20	2085-2098	deterioration	_
13-21	2099-2100	.	_

14-1	2101-2104	2.2	_
14-2	2105-2106	.	_

15-1	2107-2115	Clinical	_
15-2	2116-2126	assessment	_
15-3	2127-2136	Diagnoses	_
15-4	2137-2141	were	_
15-5	2142-2151	conducted	_
15-6	2152-2154	at	_
15-7	2155-2163	baseline	_
15-8	2164-2168	with	_
15-9	2169-2172	the	_
15-10	2173-2183	Structured	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
15-11	2184-2192	Clinical	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
15-12	2193-2202	Interview	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
15-13	2203-2206	for	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
15-14	2207-2216	DSM-IV-TR	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
15-15	2217-2218	,	_
15-16	2219-2223	Axis	_
15-17	2224-2226	I.	_
15-18	2227-2244	Socio-demographic	_
15-19	2245-2249	data	_
15-20	2250-2254	were	_
15-21	2255-2264	collected	_
15-22	2265-2267	by	_
15-23	2268-2270	an	_
15-24	2271-2280	interview	_
15-25	2281-2290	completed	_
15-26	2291-2293	by	_
15-27	2294-2301	experts	_
15-28	2302-2303	.	_

16-1	2304-2312	Clinical	_
16-2	2313-2323	assessment	_
16-3	2324-2327	was	_
16-4	2328-2335	carried	_
16-5	2336-2339	out	_
16-6	2340-2344	with	_
16-7	2345-2348	the	_
16-8	2349-2354	Brief	http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale
16-9	2355-2366	Psychiatric	http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale
16-10	2367-2373	Rating	http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale
16-11	2374-2379	Scale	http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale
16-12	2380-2381	(	http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale
16-13	2382-2386	BPRS	http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale
16-14	2387-2388	)	http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale
16-15	2389-2391	to	_
16-16	2392-2400	evaluate	_
16-17	2401-2409	severity	_
16-18	2410-2413	and	_
16-19	2414-2420	change	_
16-20	2421-2423	of	_
16-21	2424-2433	psychotic	_
16-22	2434-2437	and	_
16-23	2438-2442	mood	_
16-24	2443-2451	symptoms	_
16-25	2452-2453	.	_

17-1	2454-2463	Cognitive	_
17-2	2464-2471	insight	_
17-3	2472-2475	was	_
17-4	2476-2486	quantified	_
17-5	2487-2491	with	_
17-6	2492-2495	the	_
17-7	2496-2500	BCIS	_
17-8	2501-2512	self-report	_
17-9	2513-2522	inventory	_
17-10	2523-2524	.	_

18-1	2525-2528	The	_
18-2	2529-2538	subscales	_
18-3	2539-2540	“	_
18-4	2541-2560	self-reflectiveness	_
18-5	2561-2562	”	_
18-6	2563-2564	(	_
18-7	2565-2571	formed	_
18-8	2572-2574	by	_
18-9	2575-2576	9	_
18-10	2577-2582	items	_
18-11	2583-2584	)	_
18-12	2585-2588	and	_
18-13	2589-2590	“	_
18-14	2591-2605	self-certainty	_
18-15	2606-2607	”	_
18-16	2608-2609	(	_
18-17	2610-2616	formed	_
18-18	2617-2619	by	_
18-19	2620-2621	6	_
18-20	2622-2627	items	_
18-21	2628-2629	)	_
18-22	2630-2633	are	_
18-23	2634-2641	defined	_
18-24	2642-2644	to	_
18-25	2645-2652	measure	_
18-26	2653-2661	separate	_
18-27	2662-2669	aspects	_
18-28	2670-2672	of	_
18-29	2673-2682	cognitive	_
18-30	2683-2690	insight	_
18-31	2691-2692	.	_

19-1	2693-2697	They	_
19-2	2698-2702	rate	_
19-3	2703-2706	the	_
19-4	2707-2715	patients	_
19-5	2716-2717	'	_
19-6	2718-2725	ability	_
19-7	2726-2728	to	_
19-8	2729-2736	observe	_
19-9	2737-2742	their	_
19-10	2743-2749	mental	_
19-11	2750-2761	productions	_
19-12	2762-2765	and	_
19-13	2766-2768	to	_
19-14	2769-2776	reflect	_
19-15	2777-2779	on	_
19-16	2780-2791	alternative	_
19-17	2792-2804	explanations	_
19-18	2805-2808	and	_
19-19	2809-2823	overconfidence	_
19-20	2824-2826	in	_
19-21	2827-2830	the	_
19-22	2831-2839	validity	_
19-23	2840-2842	of	_
19-24	2843-2848	their	_
19-25	2849-2856	beliefs	_
19-26	2857-2858	.	_

20-1	2859-2870	Accordingly	_
20-2	2871-2872	,	_
20-3	2873-2878	among	_
20-4	2879-2888	psychotic	_
20-5	2889-2897	patients	_
20-6	2898-2900	an	_
20-7	2901-2908	optimal	_
20-8	2909-2918	cognitive	_
20-9	2919-2926	insight	_
20-10	2927-2929	is	_
20-11	2930-2935	given	_
20-12	2936-2938	by	_
20-13	2939-2942	the	_
20-14	2943-2950	results	_
20-15	2951-2953	of	_
20-16	2954-2958	high	_
20-17	2959-2978	self-reflectiveness	_
20-18	2979-2982	and	_
20-19	2983-2986	low	_
20-20	2987-3001	self-certainty	_
20-21	3002-3003	;	_
20-22	3004-3005	a	_
20-23	3006-3015	composite	_
20-24	3016-3021	index	_
20-25	3022-3032	reflecting	_
20-26	3033-3042	cognitive	_
20-27	3043-3050	insight	_
20-28	3051-3053	is	_
20-29	3054-3057	the	_
20-30	3058-3067	resulting	_
20-31	3068-3078	difference	_
20-32	3079-3086	between	_
20-33	3087-3090	the	_
20-34	3091-3094	two	_
20-35	3095-3101	series	_
20-36	3102-3103	.	_

21-1	3104-3106	In	_
21-2	3107-3110	the	_
21-3	3111-3118	absence	_
21-4	3119-3121	of	_
21-5	3122-3131	cognitive	_
21-6	3132-3139	insight	_
21-7	3140-3141	,	_
21-8	3142-3146	this	_
21-9	3147-3152	index	_
21-10	3153-3157	will	_
21-11	3158-3162	have	_
21-12	3163-3171	negative	_
21-13	3172-3178	values	_
21-14	3179-3180	.	_

22-1	3181-3184	2.3	_
22-2	3185-3186	.	_

23-1	3187-3194	FDG-PET	http://maven.renci.org/NeuroBridge/neurobridge#PositronEmissionTomography
23-2	3195-3203	scanning	http://maven.renci.org/NeuroBridge/neurobridge#PositronEmissionTomography
23-3	3204-3211	FDG-PET	http://maven.renci.org/NeuroBridge/neurobridge#PositronEmissionTomography
23-4	3212-3220	scanning	http://maven.renci.org/NeuroBridge/neurobridge#PositronEmissionTomography
23-5	3221-3224	was	_
23-6	3225-3234	performed	_
23-7	3235-3241	within	_
23-8	3242-3243	7	_
23-9	3244-3248	days	_
23-10	3249-3251	of	_
23-11	3252-3259	insight	_
23-12	3260-3263	and	_
23-13	3264-3271	symptom	_
23-14	3272-3282	assessment	_
23-15	3283-3284	.	_

24-1	3285-3293	Patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
24-2	3294-3303	underwent	_
24-3	3304-3311	FDG-PET	http://maven.renci.org/NeuroBridge/neurobridge#PositronEmissionTomography
24-4	3312-3314	at	_
24-5	3315-3319	rest	_
24-6	3320-3321	,	_
24-7	3322-3327	after	_
24-8	3328-3339	intravenous	_
24-9	3340-3349	injection	_
24-10	3350-3352	of	_
24-11	3353-3356	170	_
24-12	3357-3360	MBq	_
24-13	3361-3362	.	_

25-1	3363-3367	Each	_
25-2	3368-3379	acquisition	_
25-3	3380-3388	included	_
25-4	3389-3390	a	_
25-5	3391-3399	Computed	http://maven.renci.org/NeuroBridge/neurobridge#ComputedTomographyScan
25-6	3400-3410	Tomography	http://maven.renci.org/NeuroBridge/neurobridge#ComputedTomographyScan
25-7	3411-3412	(	http://maven.renci.org/NeuroBridge/neurobridge#ComputedTomographyScan
25-8	3413-3415	CT	http://maven.renci.org/NeuroBridge/neurobridge#ComputedTomographyScan
25-9	3416-3417	)	http://maven.renci.org/NeuroBridge/neurobridge#ComputedTomographyScan
25-10	3418-3430	transmission	_
25-11	3431-3435	scan	_
25-12	3436-3438	of	_
25-13	3439-3442	the	_
25-14	3443-3447	head	_
25-15	3448-3449	(	_
25-16	3450-3455	50mAs	_
25-17	3456-3463	lasting	_
25-18	3464-3466	16	_
25-19	3467-3474	seconds	_
25-20	3475-3476	)	_
25-21	3477-3485	followed	_
25-22	3486-3488	by	_
25-23	3489-3490	a	_
25-24	3491-3508	three-dimensional	_
25-25	3509-3510	(	_
25-26	3511-3513	3D	_
25-27	3514-3515	)	_
25-28	3516-3522	static	_
25-29	3523-3531	emission	_
25-30	3532-3534	of	_
25-31	3535-3537	15	_
25-32	3538-3545	minutes	_
25-33	3546-3551	using	_
25-34	3552-3553	a	_
25-35	3554-3562	Biograph	_
25-36	3563-3572	Truepoint	_
25-37	3573-3575	64	_
25-38	3576-3582	PET/CT	_
25-39	3583-3590	scanner	_
25-40	3591-3592	(	_
25-41	3593-3600	Siemens	_
25-42	3601-3602	)	_
25-43	3603-3604	.	_

26-1	3605-3612	FDG-PET	http://maven.renci.org/NeuroBridge/neurobridge#PositronEmissionTomography
26-2	3613-3621	sections	_
26-3	3622-3626	were	_
26-4	3627-3640	reconstructed	_
26-5	3641-3646	using	_
26-6	3647-3649	an	_
26-7	3650-3659	iterative	_
26-8	3660-3669	algorithm	_
26-9	3670-3671	(	_
26-10	3672-3677	OS-EM	_
26-11	3678-3679	)	_
26-12	3680-3681	,	_
26-13	3682-3691	corrected	_
26-14	3692-3695	for	_
26-15	3696-3703	scatter	_
26-16	3704-3707	and	_
26-17	3708-3711	for	_
26-18	3712-3723	attenuation	_
26-19	3724-3729	using	_
26-20	3730-3737	density	_
26-21	3738-3750	coefficients	_
26-22	3751-3758	derived	_
26-23	3759-3763	from	_
26-24	3764-3767	the	_
26-25	3768-3771	low	_
26-26	3772-3776	dose	_
26-27	3777-3779	CT	_
26-28	3780-3784	scan	_
26-29	3785-3787	of	_
26-30	3788-3791	the	_
26-31	3792-3796	head	_
26-32	3797-3805	obtained	_
26-33	3806-3810	with	_
26-34	3811-3814	the	_
26-35	3815-3819	same	_
26-36	3820-3827	scanner	_
26-37	3828-3829	,	_
26-38	3830-3834	with	_
26-39	3835-3838	the	_
26-40	3839-3850	proprietary	_
26-41	3851-3859	software	_
26-42	3860-3861	.	_

27-1	3862-3868	Images	_
27-2	3869-3873	were	_
27-3	3874-3887	reconstructed	_
27-4	3888-3890	in	_
27-5	3891-3894	the	_
27-6	3895-3899	form	_
27-7	3900-3902	of	_
27-8	3903-3913	transaxial	_
27-9	3914-3920	images	_
27-10	3921-3923	of	_
27-11	3924-3931	128×128	_
27-12	3932-3938	pixels	_
27-13	3939-3941	of	_
27-14	3942-3943	2	_
27-15	3944-3946	mm	_
27-16	3947-3948	,	_
27-17	3949-3954	using	_
27-18	3955-3957	an	_
27-19	3958-3967	iterative	_
27-20	3968-3977	algorithm	_
27-21	3978-3979	,	_
27-22	3980-3994	ordered-subset	_
27-23	3995-4006	expectation	_
27-24	4007-4019	maximization	_
27-25	4020-4021	(	_
27-26	4022-4026	OSEM	_
27-27	4027-4028	)	_
27-28	4029-4030	.	_

28-1	4031-4034	The	_
28-2	4035-4045	resolution	_
28-3	4046-4048	of	_
28-4	4049-4052	the	_
28-5	4053-4056	PET	http://maven.renci.org/NeuroBridge/neurobridge#PositronEmissionTomography
28-6	4057-4063	system	_
28-7	4064-4067	was	_
28-8	4068-4071	4–5	_
28-9	4072-4074	mm	_
28-10	4075-4079	FWHM	_
28-11	4080-4081	.	_

29-1	4082-4085	2.4	_
29-2	4086-4087	.	_

30-1	4088-4099	Statistical	_
30-2	4100-4108	analysis	_
30-3	4109-4112	The	_
30-4	4113-4124	statistical	_
30-5	4125-4133	analyses	_
30-6	4134-4138	were	_
30-7	4139-4148	performed	_
30-8	4149-4154	using	_
30-9	4155-4166	Statistical	_
30-10	4167-4177	Parametric	_
30-11	4178-4185	Mapping	_
30-12	4186-4187	(	_
30-13	4188-4192	SPM8	_
30-14	4193-4194	,	_
30-15	4195-4203	Wellcome	_
30-16	4204-4214	Department	_
30-17	4215-4217	of	_
30-18	4218-4227	Cognitive	_
30-19	4228-4237	Neurology	_
30-20	4238-4239	,	_
30-21	4240-4246	London	_
30-22	4247-4248	,	_
30-23	4249-4251	UK	_
30-24	4252-4253	)	_
30-25	4254-4255	.	_

31-1	4256-4259	FDG	http://maven.renci.org/NeuroBridge/neurobridge#Thing
31-2	4260-4263	PET	http://maven.renci.org/NeuroBridge/neurobridge#PositronEmissionTomography
31-3	4264-4268	data	_
31-4	4269-4273	were	_
31-5	4274-4283	subjected	_
31-6	4284-4286	to	_
31-7	4287-4293	affine	_
31-8	4294-4297	and	_
31-9	4298-4307	nonlinear	_
31-10	4308-4315	spatial	_
31-11	4316-4329	normalization	_
31-12	4330-4334	into	_
31-13	4335-4338	the	_
31-14	4339-4342	MNI	_
31-15	4343-4348	space	_
31-16	4349-4350	.	_

32-1	4351-4354	The	_
32-2	4355-4364	spatially	_
32-3	4365-4375	normalized	_
32-4	4376-4379	set	_
32-5	4380-4382	of	_
32-6	4383-4389	images	_
32-7	4390-4393	was	_
32-8	4394-4402	smoothed	_
32-9	4403-4407	with	_
32-10	4408-4410	an	_
32-11	4411-4414	8mm	_
32-12	4415-4424	isotropic	_
32-13	4425-4433	Gaussian	_
32-14	4434-4440	filter	_
32-15	4441-4443	to	_
32-16	4444-4448	blur	_
32-17	4449-4452	for	_
32-18	4453-4463	individual	_
32-19	4464-4474	variations	_
32-20	4475-4477	in	_
32-21	4478-4483	gyral	_
32-22	4484-4491	anatomy	_
32-23	4492-4495	and	_
32-24	4496-4504	increase	_
32-25	4505-4508	the	_
32-26	4509-4524	signal-to-noise	_
32-27	4525-4530	ratio	_
32-28	4531-4532	.	_

33-1	4533-4539	Images	_
33-2	4540-4544	were	_
33-3	4545-4553	globally	_
33-4	4554-4564	normalized	_
33-5	4565-4567	to	_
33-6	4568-4570	50	_
33-7	4571-4576	using	_
33-8	4577-4589	proportional	_
33-9	4590-4597	scaling	_
33-10	4598-4600	to	_
33-11	4601-4607	remove	_
33-12	4608-4619	confounding	_
33-13	4620-4627	effects	_
33-14	4628-4630	to	_
33-15	4631-4637	global	_
33-16	4638-4646	cerebral	_
33-17	4647-4654	glucose	_
33-18	4655-4666	consumption	_
33-19	4667-4674	changes	_
33-20	4675-4676	,	_
33-21	4677-4681	with	_
33-22	4682-4683	a	_
33-23	4684-4691	masking	_
33-24	4692-4701	threshold	_
33-25	4702-4704	of	_
33-26	4705-4708	0.8	_
33-27	4709-4710	.	_

34-1	4711-4719	Subjects	_
34-2	4720-4724	were	_
34-3	4725-4732	divided	_
34-4	4733-4737	into	_
34-5	4738-4742	four	_
34-6	4743-4749	groups	_
34-7	4750-4761	considering	_
34-8	4762-4765	the	_
34-9	4766-4770	BCIS	_
34-10	4771-4776	score	_
34-11	4777-4778	(	_
34-12	4779-4782	low	_
34-13	4783-4790	insight	_
34-14	4791-4795	with	_
34-15	4796-4799	R-C	_
34-16	4800-4801	=	_
34-17	4802-4803	<	_
34-18	4804-4805	5	_
34-19	4806-4809	and	_
34-20	4810-4814	high	_
34-21	4815-4822	insight	_
34-22	4823-4827	with	_
34-23	4828-4831	R-C	_
34-24	4832-4833	>	_
34-25	4834-4835	5	_
34-26	4836-4837	,	_
34-27	4838-4841	see	_
34-28	4842-4847	Table	_
34-29	4848-4849	3	_
34-30	4850-4851	)	_
34-31	4852-4855	and	_
34-32	4856-4859	the	_
34-33	4860-4869	diagnosis	_
34-34	4870-4871	(	_
34-35	4872-4881	affective	_
34-36	4882-4884	vs	_
34-37	4885-4888	non	_
34-38	4889-4898	affective	_
34-39	4899-4908	psychosis	_
34-40	4909-4910	)	_
34-41	4911-4912	.	_

35-1	4913-4916	The	_
35-2	4917-4923	choice	_
35-3	4924-4926	of	_
35-4	4927-4930	the	_
35-5	4931-4938	cut-off	_
35-6	4939-4941	of	_
35-7	4942-4943	5	_
35-8	4944-4946	to	_
35-9	4947-4953	divide	_
35-10	4954-4957	the	_
35-11	4958-4961	two	_
35-12	4962-4969	FDG-PET	_
35-13	4970-4976	groups	_
35-14	4977-4981	with	_
35-15	4982-4991	different	_
35-16	4992-4996	BCIS	_
35-17	4997-5006	composite	_
35-18	5007-5012	index	_
35-19	5013-5018	score	_
35-20	5019-5020	(	_
35-21	5021-5022	=	_
35-22	5023-5024	<	_
35-23	5025-5026	5	_
35-24	5027-5030	and	_
35-25	5031-5032	>	_
35-26	5033-5034	5	_
35-27	5035-5036	)	_
35-28	5037-5040	was	_
35-29	5041-5050	motivated	_
35-30	5051-5053	by	_
35-31	5054-5057	the	_
35-32	5058-5065	average	_
35-33	5066-5071	value	_
35-34	5072-5073	(	_
35-35	5074-5078	4,64	_
35-36	5079-5080	)	_
35-37	5081-5086	shown	_
35-38	5087-5089	in	_
35-39	5090-5099	psychotic	_
35-40	5100-5108	patients	_
35-41	5109-5111	in	_
35-42	5112-5115	the	_
35-43	5116-5126	literature	_
35-44	5127-5128	,	_
35-45	5129-5136	similar	_
35-46	5137-5139	to	_
35-47	5140-5143	the	_
35-48	5144-5150	median	_
35-49	5151-5155	BCIS	_
35-50	5156-5162	scores	_
35-51	5163-5165	of	_
35-52	5166-5169	our	_
35-53	5170-5175	group	_
35-54	5176-5178	of	_
35-55	5179-5187	patients	_
35-56	5188-5189	.	_

36-1	5190-5192	We	_
36-2	5193-5202	performed	_
36-3	5203-5213	two-sample	_
36-4	5214-5220	t-test	_
36-5	5221-5228	between	_
36-6	5229-5232	the	_
36-7	5233-5236	low	_
36-8	5237-5240	and	_
36-9	5241-5244	the	_
36-10	5245-5249	high	_
36-11	5250-5257	insight	_
36-12	5258-5264	groups	_
36-13	5265-5267	to	_
36-14	5268-5277	determine	_
36-15	5278-5280	if	_
36-16	5281-5284	the	_
36-17	5285-5289	data	_
36-18	5290-5294	were	_
36-19	5295-5308	significantly	_
36-20	5309-5318	different	_
36-21	5319-5320	,	_
36-22	5321-5332	considering	_
36-23	5333-5334	P	_
36-24	5335-5341	values	_
36-25	5342-5343	<	_
36-26	5344-5348	0.05	_
36-27	5349-5351	as	_
36-28	5352-5365	statistically	_
36-29	5366-5377	significant	_
36-30	5378-5379	.	_

37-1	5380-5382	We	_
37-2	5383-5388	found	_
37-3	5389-5391	no	_
37-4	5392-5403	statistical	_
37-5	5404-5415	differences	_
37-6	5416-5423	between	_
37-7	5424-5427	the	_
37-8	5428-5431	two	_
37-9	5432-5438	groups	_
37-10	5439-5441	in	_
37-11	5442-5445	any	_
37-12	5446-5448	of	_
37-13	5449-5452	the	_
37-14	5453-5464	demographic	_
37-15	5465-5467	or	_
37-16	5468-5476	clinical	_
37-17	5477-5486	variables	_
37-18	5487-5495	employed	_
37-19	5496-5498	in	_
37-20	5499-5503	this	_
37-21	5504-5509	study	_
37-22	5510-5511	,	_
37-23	5512-5521	including	_
37-24	5522-5525	age	_
37-25	5526-5527	(	_
37-26	5528-5529	p	_
37-27	5530-5531	=	_
37-28	5532-5537	0,335	_
37-29	5538-5539	)	_
37-30	5540-5541	,	_
37-31	5542-5545	sex	_
37-32	5546-5547	(	_
37-33	5548-5550	χ2	_
37-34	5551-5552	=	_
37-35	5553-5558	0,544	_
37-36	5559-5560	,	_
37-37	5561-5562	p	_
37-38	5563-5564	=	_
37-39	5565-5570	0,461	_
37-40	5571-5572	)	_
37-41	5573-5581	duration	_
37-42	5582-5584	of	_
37-43	5585-5592	illness	_
37-44	5593-5594	(	_
37-45	5595-5596	p	_
37-46	5597-5598	=	_
37-47	5599-5604	0,123	_
37-48	5605-5606	)	_
37-49	5607-5610	and	_
37-50	5611-5614	the	_
37-51	5615-5619	BPRS	_
37-52	5620-5626	scores	_
37-53	5627-5628	(	_
37-54	5629-5630	p	_
37-55	5631-5632	=	_
37-56	5633-5638	0,142	_
37-57	5639-5640	)	_
37-58	5641-5642	.	_

38-1	5643-5650	Finally	_
38-2	5651-5652	,	_
38-3	5653-5655	we	_
38-4	5656-5661	found	_
38-5	5662-5664	no	_
38-6	5665-5676	significant	_
38-7	5677-5688	differences	_
38-8	5689-5696	between	_
38-9	5697-5700	the	_
38-10	5701-5704	two	_
38-11	5705-5711	groups	_
38-12	5712-5715	for	_
38-13	5716-5719	the	_
38-14	5720-5729	diagnosis	_
38-15	5730-5731	(	_
38-16	5732-5734	χ2	_
38-17	5735-5736	=	_
38-18	5737-5742	0,049	_
38-19	5743-5744	,	_
38-20	5745-5746	p	_
38-21	5747-5748	=	_
38-22	5749-5754	0,825	_
38-23	5755-5756	)	_
38-24	5757-5758	.	_

39-1	5759-5770	Significant	_
39-2	5771-5782	differences	_
39-3	5783-5785	in	_
39-4	5786-5791	brain	_
39-5	5792-5802	metabolism	_
39-6	5803-5808	among	_
39-7	5809-5812	the	_
39-8	5813-5817	four	_
39-9	5818-5824	groups	_
39-10	5825-5826	(	_
39-11	5827-5830	non	_
39-12	5831-5840	affective	_
39-13	5841-5850	psychosis	_
39-14	5851-5855	with	_
39-15	5856-5859	low	_
39-16	5860-5867	insight	_
39-17	5868-5869	,	_
39-18	5870-5873	non	_
39-19	5874-5883	affective	_
39-20	5884-5893	psychosis	_
39-21	5894-5898	with	_
39-22	5899-5903	high	_
39-23	5904-5911	insight	_
39-24	5912-5913	,	_
39-25	5914-5923	affective	_
39-26	5924-5933	psychosis	_
39-27	5934-5938	with	_
39-28	5939-5942	low	_
39-29	5943-5950	insight	_
39-30	5951-5952	,	_
39-31	5953-5956	and	_
39-32	5957-5966	affective	_
39-33	5967-5976	psychosis	_
39-34	5977-5981	with	_
39-35	5982-5986	high	_
39-36	5987-5994	insight	_
39-37	5995-5996	)	_
39-38	5997-6001	were	_
39-39	6002-6011	estimated	_
39-40	6012-6014	by	_
39-41	6015-6020	means	_
39-42	6021-6023	of	_
39-43	6024-6038	single-subject	_
39-44	6039-6040	,	_
39-45	6041-6051	conditions	_
39-46	6052-6055	and	_
39-47	6056-6066	covariates	_
39-48	6067-6073	design	_
39-49	6074-6075	,	_
39-50	6076-6080	with	_
39-51	6081-6084	the	_
39-52	6085-6086	4	_
39-53	6087-6093	groups	_
39-54	6094-6096	of	_
39-55	6097-6106	psychosis	_
39-56	6107-6114	modeled	_
39-57	6115-6117	as	_
39-58	6118-6128	conditions	_
39-59	6129-6130	,	_
39-60	6131-6135	with	_
39-61	6136-6143	insight	_
39-62	6144-6149	score	_
39-63	6150-6152	as	_
39-64	6153-6162	covariate	_
39-65	6163-6171	variable	_
39-66	6172-6174	of	_
39-67	6175-6178	all	_
39-68	6179-6187	patients	_
39-69	6188-6191	and	_
39-70	6192-6195	age	_
39-71	6196-6198	as	_
39-72	6199-6202	the	_
39-73	6203-6211	nuisance	_
39-74	6212-6220	variable	_
39-75	6221-6224	for	_
39-76	6225-6230	group	_
39-77	6231-6239	analyses	_
39-78	6240-6241	.	_

40-1	6242-6247	First	_
40-2	6248-6249	,	_
40-3	6250-6252	we	_
40-4	6253-6262	performed	_
40-5	6263-6264	a	_
40-6	6265-6272	one-way	_
40-7	6273-6281	analysis	_
40-8	6282-6284	of	_
40-9	6285-6293	variance	_
40-10	6294-6295	(	_
40-11	6296-6301	ANOVA	_
40-12	6302-6303	)	_
40-13	6304-6311	between	_
40-14	6312-6315	the	_
40-15	6316-6320	four	_
40-16	6321-6327	groups	_
40-17	6328-6329	.	_

41-1	6330-6334	Then	_
41-2	6335-6336	,	_
41-3	6337-6339	we	_
41-4	6340-6349	performed	_
41-5	6350-6360	two-sample	_
41-6	6361-6367	t-test	_
41-7	6368-6375	between	_
41-8	6376-6380	pair	_
41-9	6381-6383	of	_
41-10	6384-6390	groups	_
41-11	6391-6395	with	_
41-12	6396-6399	low	_
41-13	6400-6407	insight	_
41-14	6408-6416	compared	_
41-15	6417-6419	to	_
41-16	6420-6425	those	_
41-17	6426-6430	with	_
41-18	6431-6435	high	_
41-19	6436-6443	insight	_
41-20	6444-6445	.	_

42-1	6446-6449	All	_
42-2	6450-6461	voxel-based	_
42-3	6462-6473	statistical	_
42-4	6474-6482	analyses	_
42-5	6483-6485	of	_
42-6	6486-6491	brain	_
42-7	6492-6499	glucose	_
42-8	6500-6510	metabolism	_
42-9	6511-6517	images	_
42-10	6518-6522	were	_
42-11	6523-6532	performed	_
42-12	6533-6535	by	_
42-13	6536-6544	applying	_
42-14	6545-6546	a	_
42-15	6547-6558	statistical	_
42-16	6559-6568	threshold	_
42-17	6569-6571	of	_
42-18	6572-6583	uncorrected	_
42-19	6584-6585	p	_
42-20	6586-6587	<	_
42-21	6588-6593	0.005	_
42-22	6594-6596	at	_
42-23	6597-6602	voxel	_
42-24	6603-6608	level	_
42-25	6609-6612	for	_
42-26	6613-6619	F-test	_
42-27	6620-6623	and	_
42-28	6624-6625	p	_
42-29	6626-6627	<	_
42-30	6628-6633	0.005	_
42-31	6634-6643	corrected	_
42-32	6644-6646	at	_
42-33	6647-6654	cluster	_
42-34	6655-6660	level	_
42-35	6661-6664	for	_
42-36	6665-6671	t-test	_
42-37	6672-6673	,	_
42-38	6674-6678	with	_
42-39	6679-6681	an	_
42-40	6682-6688	extent	_
42-41	6689-6698	threshold	_
42-42	6699-6701	of	_
42-43	6702-6704	at	_
42-44	6705-6710	least	_
42-45	6711-6713	35	_
42-46	6714-6724	contiguous	_
42-47	6725-6731	voxels	_
42-48	6732-6733	.	_

43-1	6734-6735	P	_
43-2	6736-6742	values	_
43-3	6743-6744	<	_
43-4	6745-6750	0.005	_
43-5	6751-6755	were	_
43-6	6756-6766	considered	_
43-7	6767-6780	statistically	_
43-8	6781-6792	significant	_
43-9	6793-6795	in	_
43-10	6796-6804	analysis	_
43-11	6805-6807	of	_
43-12	6808-6818	covariance	_
43-13	6819-6821	to	_
43-14	6822-6831	correlate	_
43-15	6832-6835	the	_
43-16	6836-6845	cognitive	_
43-17	6846-6853	insight	_
43-18	6854-6859	score	_
43-19	6860-6864	with	_
43-20	6865-6868	the	_
43-21	6869-6879	metabolism	_
43-22	6880-6881	.	_

